29th Early Detection Research Network (EDRN) Steering Committee Meeting March 31, 2015 – April 2, 2015 Emory Conference Center Hotel, Atlanta, Georgia

Gastrointestinal & Associated Cancers Collaborative Group Meeting Tuesday, March 31, 2015 1:30 p.m. – 5:30 p.m. Salon IV&V

Chair:

Michael (Tony) Hollingsworth, Ph.D., University of Nebraska Medical Center

NCI Program Directors:

Jo Ann Rinaudo, Ph.D., National Cancer Institute Matthew Young, Ph.D., National Cancer Institute

Agenda

1:30 p.m. – 1:35 p.m.	Opening Remarks Michael (Tony) Hollingsworth, Ph.D., University of Nebraska Medical Center
1:35 p.m. – 1:40 p.m.	Introduction: New Program Director Matthew Young, Ph.D., National Cancer Institute
1:40 p.m. – 2:05 p.m.	The Path in Validating Gal-3 Ligand as a Biomarker for Colorectal Cancer David Chia, Ph.D., University of California, Los Angeles
2:05 p.m. – 2:30 p.m.	Biomarker Based Detection of Barrett's Esophagus and Esophageal Adenocarcinomas Sanford Markowitz, M.D., Ph.D., Case Western Reserve University
2:30 p.m. – 2:55 p.m.	Validation Studies Using the EDRN Pancreatic Cancer Reference Set Ann Killary, Ph.D., and Seetharaman Balasenthil, Ph.D., The University of Texas MD Anderson Cancer Center
2:55 p.m. – 3:20 p.m.	Accurate Identification of Pancreatic Cancer Using Glycan Biomarkers in the Plasma Brian Haab, Ph.D., Van Andel Institute
3:20 p.m. – 3:45 p.m.	A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer - <u>A Multicenter Study</u> Surinder Batra, Ph.D., University of Nebraska Medical Center
3:45 p.m. – 4:00 p.m.	Break
4:00 p.m. – 4:25 p.m.	Resources for Pancreatic Cancer Research: Status of Pancreatic Adenocarcinoma and Cystic Neoplasm Reference Sets Randall Brand, M.D., University of Pittsburgh Jo Ann Rinaudo, Ph.D., National Cancer Institute
4:25 p.m. – 4:50 p.m.	<u>Future Validation Studies: Colon Cancer Study – GLNE010</u> Dean Brenner, M.D., University of Michigan
4:50 p.m. – 5:15 p.m.	Colorectal Cancer Early Detection: Strategies & Prototypes for Biomarker Panels/Algorithms Gerard Davis, Ph.D., Abbott Laboratories
5:15 p.m. – 5:30 p.m.	Group Discussion
5:30 p.m.	Adjourn